The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BSH/ISH 2016 | Next steps for advancing the molecular stratification of CLL
Anna Schuh, MD, PhD, from the University of Oxford, Oxford, UK, disucsses the next steps for advancing the molecular stratification and treatment of chronic lymphocytic leukemia (CLL). Dr Schuh discusses the Genomics England project, which will look at the whole genome data and willl allow researchers to discover more clinically relevant mutations. This will further allow for a better stratification of patients according to Dr Schuh.
Recorded at the 2016 Annual Meeting of the British Society of Haematology (BSH) and International Society of Hematology (ISH), held in Glasgow, Scotland.
